The 4T1 Cell Line Shows Increased Radiosensitivity When Treated With ATR Inhibitors
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With the higher concentration of ATRi (0.5 µM), 4T1 cells
are more radiosensitive than the lower concentration of
ATRi (0.1 µM) and the vehicle for both x-rays and protons.
We found that the ATR inhibitor is a more effective
radiosensitizer to protons than to photons likely because
protons are more densely ionizing resulting in more complex
DNA breaks. Additionally, 1 µM of the ATR inhibitor greatly
senstizes 4T1 cells to photons.

Discussion
Utilizing photon radiation therapy contributes towards
approximately 40% of curative cancer treatments (Baskar et
al.). Furthermore, proton radiation therapy allows for greater
specificity towards targeting carcinogenic tissue, decreasing
irradiation of healthy tissue (Suit and Urie). When
considering tumors located in delicate areas of the body,
such as the brain, it is vital to apply the greatest direct
dosage, while keeping irradiation to non-target areas to a
minimum. Hence, The addition of inhibiting drugs, such as
ATRi, sensitizes cells, allowing for cell death, and therefore
tumor shrinkage, to be achieved using smaller, less toxic
doses.
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Figure 3: The RBE values across all concentrations
and the vehicle (DMSO) is above 1.5 indicating
proton therapy is effective.
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Figure 2: The higher concentrations of ATR (1 µM and 0.5
µM) achieve 10% survival with lower doses of radiation in
comparison to the vehicle and lower concentration (0.1 µM)
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Figure 1: 10% survival is achieved using lower doses of
proton therapy with the higher concentration of ATR (0.5µM).
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We performed clonogenic assays with 4T1 cells, treated with and
without an ATRi (AZD6738). This was done at concentrations of 0.1 µM
and 0.5 µM, with DMSO used as vehicle. The cells were then irradiated
with 6 MV x-rays or 9.9 keV/µm protons. At least 3 independent repeats
were done for each condition. To quantify drug sensitization at a given
radiation quality, we used the sensitization enhancement ratio, SER:
SER=D10%,DMSO/D10%,AZD6738, where D10% is dose at 10% survival
fraction.
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Hypothesis
Increasing concentrations of ATRi added to the 4T1 cell line will
radiosensitize cells to proton and photon radiation.

The SER value for the 4T1 at D10%, when treated with x-rays
and ATRi (0.1 µM), was found to be 0.96 ± 0.16. With the
higher concentration of ATRi (0.5 µM), the SER value was
found to be 1.17 ± 0.12. This indicates that 4T1 cells are
more radiosensitive at higher concentrations of ATRi. The
SER value for the 4T1 cells treated with the low
concentration of the ATRi (0.1 µM) and 9.9 keV/µm protons
was 0.88 ± 0.13 while the SER value for the higher
concentration (0.5 µM of AZD6738) was 1.26 ± 0.14.

0 .1 M

S u r v iv i n g F r a c t io n

The ataxia telangiectasia and Rad3-related (ATR) protein has several
roles in DNA damage response, including DNA double-strand break
(DSB) repair through homologous recombination (HR) and cell cycle
checkpoint control at intra-S and G2 checkpoints (Mei et al.).
Combining ATR inhibitors (ATRi) with x-ray or proton radiation may lead
to synthetic lethality in cancer cells. In particular, protons may provide
synergistic effects with ATR inhibition due to their capacity to create
more clustered DSB lesions, which require a higher contribution of HR,
compared to less clustered DSB lesions induced by x-rays. In this
work, we quantified the effectiveness of ATRi in sensitizing the 4T1 cell
line, a murine triple-negative breast cancer cell line, to x-rays and
protons.

Figure 4: The low concentration of ATR (0.1µM) is below 1,
indicating that smaller concentrations of ATR do not sensitize cells
when treated with proton or photon therapy. At a concentration of
0.5 µM, the ATRi sensitizes cells, and more so in proton therapy.
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